New hope for low platelet patients: experimental drug shows promise in small trial
NCT ID NCT06287567
First seen Jan 05, 2026 · Last updated May 23, 2026 · Updated 19 times
Summary
This study tested a drug called lusutrombopag in 17 Chinese adults with persistent or chronic immune thrombocytopenia (ITP) who had not responded to standard treatments. The goal was to see if the drug could safely raise their platelet counts to safer levels. Participants took the drug for up to 12 weeks, and researchers measured how many achieved a platelet count of 50 billion per liter or higher.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IMMUNE THROMBOCYTOPENIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Institute of Hematology & Blood Diseases Hospital
Tianjin, Tianjin Municipality, 300020, China
Conditions
Explore the condition pages connected to this study.